Liu et al. reported that non-small-cell lung cancer cells treated with low-dose CDDP are sufficient to enrich CD133+ cells and upregulate ABCB1 expression through Notch signaling, which therefore increases the cross-resistance to DXR [30]. Here, ABCB1 is linked to non-small cell lung carcinoma.